Trichomoniasis is the most common, curable sexually transmitted disease in the world. The first line treatment of trichomoniasis is metronidazole. Recently, the resistance of T. vaginalis to metronidazole and imidazoles has been shown to increase. Ivermectin is a synthetic machrolid drug with activity versus endo and ectoparasitic organisms. In this assay, was tested the effects of ivermectin on T. vaginalis trophozoites. Ivermectin have anti-parasitic activity upon trichomonas trophozoites. However, the IC 50 of ivermectin against T. vaginalis was high compared with metronidazole.
|Number of pages||3|
|Journal||Latin American Journal of Pharmacy|
|Publication status||Published - 30 Apr 2012|
All Science Journal Classification (ASJC) codes
- Pharmaceutical Science
- Drug Discovery